Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
15 Mar 2022
15 Mar 2022
Historique:
received:
24
05
2021
accepted:
11
02
2022
entrez:
16
3
2022
pubmed:
17
3
2022
medline:
17
3
2022
Statut:
epublish
Résumé
Adult vaccination programs are receiving increasing attention however, little is known regarding the impact of age on the maintenance of the immune response. We investigated this issue in the context of a human papillomavirus (HPV) vaccination program collecting real-world data on the durability of humoral immunity in 315 female subjects stratified according to vaccination age (adolescents and adults) and sampled at early or late time points after the last vaccine dose. HPV-specific IgGs, but not memory B cells, were induced and maintained at higher levels in subjects vaccinated during adolescence. Nonetheless, antibody functions waned over time to a similar degree in adolescents and adults. To shed light on this phenomena, we analyzed quantitative and qualitative properties of lymphocytes. Similar biochemical features were observed between B-cell subsets from individuals belonging to the two age groups. Long term humoral responses toward vaccines administered at an earlier age were comparably maintained between adolescents and adults. The percentages of naïve B and CD4
Identifiants
pubmed: 35292655
doi: 10.1038/s41541-022-00458-0
pii: 10.1038/s41541-022-00458-0
pmc: PMC8924199
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37Informations de copyright
© 2022. The Author(s).
Références
Talbird, S. E. et al. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum. Vaccin. Immunother. 17, 332–343 (2021).
pubmed: 32758069
doi: 10.1080/21645515.2020.1780847
Doherty, T. M., Del Giudice, G. & Maggi, S. Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. Ann. Med. 51, 128–140 (2019).
pubmed: 31025882
pmcid: 7857442
doi: 10.1080/07853890.2019.1588470
Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100 (2021).
pubmed: 33353987
doi: 10.1038/s41577-020-00479-7
Kennedy, R. B., Ovsyannikova, I. G., Palese, P. & Poland, G. A. Current Challenges in Vaccinology. Front Immunol. 11, 1181 (2020).
pubmed: 32670279
pmcid: 7329983
doi: 10.3389/fimmu.2020.01181
Mehta, B., Chawla, S., Kumar, V., Jindal, H. & Bhatt, B. Adult immunization: the need to address. Hum. Vaccin. Immunother. 10, 306–309 (2014).
pubmed: 24128707
doi: 10.4161/hv.26797
Schiller, J. T., Castellsague, X. & Garland, S. M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30, F123–F138 (2012). Suppl 5.
pubmed: 23199956
pmcid: 4636904
doi: 10.1016/j.vaccine.2012.04.108
Rosenblum, H. G. et al. Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine - United States, 2003-2018. MMWR Morb. Mortal. Wkly Rep. 70, 415–420 (2021).
pubmed: 33764964
pmcid: 7993559
doi: 10.15585/mmwr.mm7012a2
Wendland, E. M. et al. Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women. Vaccine 39, 1840–1845 (2021).
pubmed: 33674171
doi: 10.1016/j.vaccine.2021.02.040
Longet, S., Schiller, J. T., Bobst, M., Jichlinski, P. & Nardelli-Haefliger, D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J. Virol. 85, 13253–13259 (2011).
pubmed: 21976653
pmcid: 3233130
doi: 10.1128/JVI.06093-11
Kwak, K., Yemelyanova, A. & Roden, R. B. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr. Opin. Immunol. 23, 244–251 (2011).
pubmed: 21185706
doi: 10.1016/j.coi.2010.11.009
Suzich, J. A. et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA 92, 11553–11557 (1995).
pubmed: 8524802
pmcid: 40440
doi: 10.1073/pnas.92.25.11553
Nicoli, F. et al. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine 34, 2216–2224 (2016).
pubmed: 27002499
doi: 10.1016/j.vaccine.2016.03.022
Anderson, S. M., Hannum, L. G. & Shlomchik, M. J. Memory B cell survival and function in the absence of secreted antibody and immune complexes on follicular dendritic cells. J. Immunol. 176, 4515–4519 (2006).
pubmed: 16585539
doi: 10.4049/jimmunol.176.8.4515
Wong, R. & Bhattacharya, D. Basics of memory B-cell responses: lessons from and for the real world. Immunology 156, 120–129 (2019).
pubmed: 30488482
doi: 10.1111/imm.13019
Briceno, O. et al. Reduced naive CD8(+) T-cell priming efficacy in elderly adults. Aging Cell 15, 14–21 (2016).
pubmed: 26472076
doi: 10.1111/acel.12384
Block, S. L. et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118, 2135–2145 (2006).
pubmed: 17079588
doi: 10.1542/peds.2006-0461
Hu, Y. M. et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci. China Life Sci. 63, 582–591 (2020).
pubmed: 31231780
doi: 10.1007/s11427-019-9547-7
Iversen, O. E. et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA 316, 2411–2421 (2016).
pubmed: 27893068
doi: 10.1001/jama.2016.17615
Ruiz-Sternberg, A. M. et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res. 5, 63–74 (2018).
pubmed: 29269325
doi: 10.1016/j.pvr.2017.12.004
Giuliano, A. R. et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J. Infect. Dis. 196, 1153–162 (2007).
pubmed: 17955433
doi: 10.1086/521679
Petersen, L. K. et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res. 3, 105–115 (2017).
pubmed: 28720442
pmcid: 5883201
doi: 10.1016/j.pvr.2017.03.002
Pasin, C. et al. Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation. J Virol. 93, e00579-19 (2019).
pubmed: 31243126
pmcid: 6714808
doi: 10.1128/JVI.00579-19
Fisman, D. N., Agrawal, D. & Leder, K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin. Infect. Dis. 35, 1368–1375 (2002).
pubmed: 12439800
doi: 10.1086/344271
Sauvageau, C. et al. The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13year-old girls: Is it influenced by age, menarche status or body mass index? Vaccine 37, 7203–7206 (2019).
pubmed: 31648910
doi: 10.1016/j.vaccine.2019.09.089
Schwarz, T. et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG 122, 107–118 (2015).
pubmed: 25208608
doi: 10.1111/1471-0528.13070
Slike, B. M., Creegan, M., Marovich, M. & Ngauy, V. Humoral immunity to primary smallpox vaccination: impact of childhood versus adult immunization on vaccinia vector vaccine development in military populations. PLoS ONE 12, e0169247 (2017).
pubmed: 28046039
pmcid: 5207489
doi: 10.1371/journal.pone.0169247
Einstein, M. H. et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum. Vaccin. Immunother. 10, 3435–3445 (2014).
pubmed: 25483701
pmcid: 4514070
doi: 10.4161/hv.36121
Sasaki, S. et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J. Clin. Invest. 121, 3109–3119 (2011).
pubmed: 21785218
pmcid: 3148747
doi: 10.1172/JCI57834
Stiasny, K., Aberle, J. H., Keller, M., Grubeck-Loebenstein, B. & Heinz, F. X. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS ONE 7, e34145 (2012).
pubmed: 22461903
pmcid: 3312914
doi: 10.1371/journal.pone.0034145
Krajden, M. et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 32, 624–630 (2014).
pubmed: 24055350
doi: 10.1016/j.vaccine.2013.09.007
Roteli-Martins, C. M. et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum. Vaccin. Immunother. 8, 390–397 (2012).
pubmed: 22327492
doi: 10.4161/hv.18865
Scherer, E. M. et al. A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects. EBioMedicine 10, 55–64 (2016).
pubmed: 27423190
pmcid: 5006801
doi: 10.1016/j.ebiom.2016.06.042
Smolen, K. K. et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 30, 3572–3579 (2012).
pubmed: 22469863
doi: 10.1016/j.vaccine.2012.03.051
Tiggelaar, S. M., Lin, M. J., Viscidi, R. P., Ji, J. & Smith, J. S. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J. Adolesc. Health 50, 110–131 (2012).
pubmed: 22265107
pmcid: 3572199
doi: 10.1016/j.jadohealth.2011.10.010
Lupi, S., Bergamini, M., Guidi, E., Gregorio, P. & Group, H. P. V. C. Cross-sectional seroprevalence of antibodies against 6, 11, 16 and 18 human papilloma virus (HPV) types among teenagers and young women in Italy. Ann.1st Super. Sanita 50, 171–177 (2014).
Desai, S. et al. Prevalence of human papillomavirus antibodies in males and females in England. Sex. Transm. Dis. 38, 622–629 (2011).
pubmed: 21317688
doi: 10.1097/OLQ.0b013e31820bc880
Newall, A. T. et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin. Infect. Dis. 46, 1647–1655 (2008).
pubmed: 18444790
doi: 10.1086/587895
Frasca, D., Diaz, A., Romero, M. & Blomberg, B. B. The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations. Vaccine 34, 2834–2840 (2016).
pubmed: 27108193
pmcid: 4876633
doi: 10.1016/j.vaccine.2016.04.023
Leyendeckers, H. et al. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur. J. Immunol. 29, 1406–1417 (1999).
pubmed: 10229109
doi: 10.1002/(SICI)1521-4141(199904)29:04<1406::AID-IMMU1406>3.0.CO;2-P
Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. New Engl. J. Med. 357, 1903–1915 (2007).
pubmed: 17989383
doi: 10.1056/NEJMoa066092
Siegrist, C. A. & Aspinall, R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9, 185–194 (2009).
pubmed: 19240757
doi: 10.1038/nri2508
Allen, J. C., Toapanta, F. R., Chen, W. & Tennant, S. M. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine 38, 8264–8272 (2020).
pubmed: 33229108
pmcid: 7719605
doi: 10.1016/j.vaccine.2020.11.002
Frasca, D., Blomberg, B. B., Garcia, D., Keilich, S. R. & Haynes, L. Age-related factors that affect B cell responses to vaccination in mice and humans. Immunol. Rev. 296, 142–154 (2020).
pubmed: 32484934
pmcid: 7371527
doi: 10.1111/imr.12864
Nguyen, D. C., Joyner, C. J., Sanz, I. & Lee, F. E. Factors affecting early antibody secreting cell maturation into long-lived plasma cells. Front. Immunol. 10, 2138 (2019).
pubmed: 31572364
pmcid: 6749102
doi: 10.3389/fimmu.2019.02138
Pilkinton, M. A. et al. Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion. Vaccine 35, 329–336 (2017).
pubmed: 27919633
doi: 10.1016/j.vaccine.2016.11.059
Lefebvre, J. S. et al. The aged microenvironment contributes to the age-related functional defects of CD4 T cells in mice. Aging Cell 11, 732–740 (2012).
pubmed: 22607653
doi: 10.1111/j.1474-9726.2012.00836.x
Eaton, S. M., Burns, E. M., Kusser, K., Randall, T. D. & Haynes, L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J. Exp. Med. 200, 1613–1622 (2004).
pubmed: 15611289
pmcid: 2211991
doi: 10.1084/jem.20041395
Kyu, H. H. et al. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health 17, 179 (2017).
pubmed: 28178973
pmcid: 5299674
doi: 10.1186/s12889-017-4111-4
Tetanus - Annual Epidemiological Report. European Centre for Disease Prevention and Control (2016).
Clemmons, N. S., Wallace, G. S., Patel, M. & Gastanaduy, P. A. Incidence of Measles in the United States, 2001-2015. JAMA 318, 1279–1281 (2017).
pubmed: 28973240
pmcid: 5727570
doi: 10.1001/jama.2017.9984
Pacenti, M. et al. Measles Virus Infection and Immunity in a Suboptimal Vaccination Coverage Setting. Vaccines (Basel) 7, 199 (2019).
Skoff, T. H. et al. Sources of Infant Pertussis Infection in the United States. Pediatrics 136, 635–641 (2015).
pubmed: 26347437
doi: 10.1542/peds.2015-1120
Nicoli, F. et al. HPV-Specific Systemic antibody responses and memory B cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy. Vaccines (Basel). 8, 26 (2020).
Buck, C. B., Pastrana, D. V., Lowy, D. R. & Schiller, J. T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78, 751–757 (2004).
pubmed: 14694107
pmcid: 368835
doi: 10.1128/JVI.78.2.751-757.2004
Barzon, L. et al. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine 32, 5357–5362 (2014).
pubmed: 25045814
doi: 10.1016/j.vaccine.2014.07.014
Sicurella, M. et al. An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLoS ONE 9, e100844 (2014).
pubmed: 25033084
pmcid: 4102458
doi: 10.1371/journal.pone.0100844
Dauner, J. G. et al. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol. Cell. Probes 26, 73–80 (2012).
pubmed: 22285687
pmcid: 3319198
doi: 10.1016/j.mcp.2012.01.002
Polanec, J., Seppala, I., Rousseau, S. & Hedman, K. Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virus. J. Clin. Lab Anal. 8, 16–21 (1994).
pubmed: 8164106
doi: 10.1002/jcla.1860080105
Nicoli, F. et al. Naive CD8(+) T-cells engage a versatile metabolic program upon activation in humans and differ energetically from memory CD8(+) T-cells. Front. Immunol. 9, 2736 (2018).
pubmed: 30619240
pmcid: 6308131
doi: 10.3389/fimmu.2018.02736
Telatin, V. et al. In chronic hepatitis C infection, myeloid-derived suppressor cell accumulation and T cell dysfunctions revert partially and late after successful direct-acting antiviral treatment. Front. Cell. Infect. Microbiol. 9, 190 (2019).
pubmed: 31259160
pmcid: 6588015
doi: 10.3389/fcimb.2019.00190
R: A Language and Environment for Statistical Computing. Vienna, Austria: R Core Team (R Foundation for Statistical Computing, 2019).
RStudio: Integrated Development Environment for R. (RStudio Team, RStudio, Inc.; 2016).
Wickham H. Tidyverse: Easily Install and Load the ‘Tidyverse’. (2017).
Wickham H. Scales: Scale Functions for Visualization (2018).